Spero Therapeutics shareholders approve 3M share increase for 2017 stock plan

Spero Therapeutics, Inc.

Stockholders approved amendment to 2017 Stock Incentive Plan, adding 3,000,000 authorized shares.
All three Class I director nominees (Scott Jackson, John C. Pottage Jr., Cynthia Smith) were reelected.
Ratification of PricewaterhouseCoopers as auditor for FY2024 passed with 36.6M votes for.
Advisory vote on executive compensation approved (23.9M for, 442k against).
Quorum of 68.23% of outstanding shares present at annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.